Sana Biotechnology, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Sana Biotechnology, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($42.15M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($93.80M) | Aug 11, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($93.80M) | Nov 6, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($49.39M) | Aug 11, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($49.39M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($49.39M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($59.92M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($50.29M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($50.29M) | Aug 11, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($107.48M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($107.48M) | May 8, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($107.48M) | Aug 11, 2025 |
| Q3 | 2024 | Sep 30, 2023 | $984.0K | Nov 8, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($114.00M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($114.00M) | Nov 8, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($82.12M) | Nov 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($82.12M) | May 8, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($82.12M) | Aug 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($85.12M) | Nov 8, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($72.47M) | Aug 3, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($43.52M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($94.98M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($50.63M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($61.76M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($49.37M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($110.72M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($2.18M) | Nov 8, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($116.29M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($84.05M) | May 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($86.19M) | Nov 8, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($72.90M) | Aug 3, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($31.69M) | May 8, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($83.43M) | Nov 2, 2022 |
| Q2 | 2022 | Jun 30, 2021 | $18.55M | Aug 4, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($180.75M) | May 10, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($51.64M) | Nov 8, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($87.91M) | Aug 4, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($33.28M) | May 5, 2021 |